{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:16:05Z","timestamp":1793376965054,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T00:00:00Z","timestamp":1463097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s11894-016-0508-y","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T09:52:19Z","timestamp":1463133139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes"],"prefix":"10.1007","volume":"18","author":[{"given":"Humberto C.","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Duarte-Rojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,13]]},"reference":[{"key":"508_CR1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CLEP.S53302","volume":"6","author":"K Thorlund","year":"2014","unstructured":"Thorlund K, Druyts E, Mills EJ. SVR12 is higher than SVR24 in treatment-naive hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. Clin Epidemiol. 2014;6:49\u201358.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"508_CR2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","volume":"61","author":"EM Yoshida","year":"2015","unstructured":"Yoshida EM et al. Concordance of sustained virological response 4, 12, and 24\u00a0weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology. 2015;61(1):41\u20135.","journal-title":"Hepatology"},{"issue":"6","key":"508_CR3","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1053\/j.gastro.2012.02.013","volume":"142","author":"AST Barritt","year":"2012","unstructured":"Barritt AST, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology. 2012;142(6):1314\u20131323 e1.","journal-title":"Gastroenterology"},{"issue":"20","key":"508_CR4","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878\u201387.","journal-title":"N Engl J Med"},{"issue":"27","key":"508_CR5","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster GR et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608\u201317.","journal-title":"N Engl J Med"},{"issue":"3","key":"508_CR6","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"Charlton M. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649\u201359. A study reporting the use of direct-acting antiviral agents in decompensated cirrhosis both in non-transplant patients and transplant recipients.","journal-title":"Gastroenterology"},{"issue":"27","key":"508_CR7","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618\u201328. A study using one of the newest combinations of antiviral agents (one active drug is not FDA approved yet) in decompensated HCV-related cirrhosis.","journal-title":"N Engl J Med"},{"issue":"24","key":"508_CR8","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ Meer van der","year":"2012","unstructured":"van der Meer AJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584\u201393.","journal-title":"JAMA"},{"issue":"3","key":"508_CR9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","volume":"52","author":"TR Morgan","year":"2010","unstructured":"Morgan TR et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52(3):833\u201344.","journal-title":"Hepatology"},{"issue":"1","key":"508_CR10","doi-asserted-by":"crossref","first-page":"252A","DOI":"10.1016\/j.jhep.2014.10.038","volume":"62","author":"LM Nyberg","year":"2015","unstructured":"Nyberg LM. The association of sustained virological response and all-cause mortality after interferon-based therapy for chronic hepatitis C in a large U.S. community-based health care delivery system. Hepatology. 2015;62(1):252A. A community-based study confirming that SVR reduces all-cause mortality.","journal-title":"Hepatology"},{"issue":"5","key":"508_CR11","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.jhep.2011.09.024","volume":"56","author":"EL Ellis","year":"2012","unstructured":"Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012;56(5):1171\u201380.","journal-title":"J Hepatol"},{"issue":"2","key":"508_CR12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209\u201318.","journal-title":"J Clin Invest"},{"issue":"2","key":"508_CR13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3181\/0707-MR-190","volume":"233","author":"T Kisseleva","year":"2008","unstructured":"Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood). 2008;233(2):109\u201322.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"4","key":"508_CR14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2008.06.049","volume":"134","author":"V Krizhanovsky","year":"2008","unstructured":"Krizhanovsky V et al. Senescence of activated stellate cells limits liver fibrosis. Cell. 2008;134(4):657\u201367.","journal-title":"Cell"},{"issue":"3","key":"508_CR15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1172\/JCI1018","volume":"102","author":"JP Iredale","year":"1998","unstructured":"Iredale JP et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 1998;102(3):538\u201349.","journal-title":"J Clin Invest"},{"issue":"Pt 2","key":"508_CR16","first-page":"183","volume":"14","author":"R Perez-Tamayo","year":"1979","unstructured":"Perez-Tamayo R. Cirrhosis of the liver: a reversible disease? Pathol Annu. 1979;14(Pt 2):183\u2013213.","journal-title":"Pathol Annu"},{"issue":"Suppl 1","key":"508_CR17","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.clinre.2015.06.015","volume":"39","author":"M Sun","year":"2015","unstructured":"Sun M, Kisseleva T. Reversibility of liver fibrosis. Clin Res Hepatol Gastroenterol. 2015;39 Suppl 1:S60\u20133.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"508_CR18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-2001-17557","volume":"21","author":"JP Iredale","year":"2001","unstructured":"Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis. 2001;21(3):427\u201336.","journal-title":"Semin Liver Dis"},{"issue":"11","key":"508_CR19","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.5858\/2000-124-1599-ROHC","volume":"124","author":"IR Wanless","year":"2000","unstructured":"Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000;124(11):1599\u2013607.","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"508_CR20","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","volume":"64","author":"YA Lee","year":"2015","unstructured":"Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64(5):830\u201341. A comprehensive review of fibrosis regression pathophysiology.","journal-title":"Gut"},{"issue":"6","key":"508_CR21","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/hep.510300624","volume":"30","author":"L Castera","year":"1999","unstructured":"Castera L et al. Pain experienced during percutaneous liver biopsy. Hepatology. 1999;30(6):1529\u201330.","journal-title":"Hepatology"},{"issue":"2","key":"508_CR22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11894-012-0307-z","volume":"15","author":"HC Gonzalez","year":"2013","unstructured":"Gonzalez HC, Jafri SM, Gordon SC. Role of liver biopsy in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013;15(2):307.","journal-title":"Curr Gastroenterol Rep"},{"issue":"7","key":"508_CR23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJM200102153440706","volume":"344","author":"AA Bravo","year":"2001","unstructured":"Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001;344(7):495\u2013500.","journal-title":"N Engl J Med"},{"key":"508_CR24","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1053\/jhep.2003.09022","volume":"38","author":"P Bedossa","year":"2003","unstructured":"Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449\u201357.","journal-title":"Hepatology"},{"key":"508_CR25","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1309\/W3XCNT4HKFBN2G0B","volume":"125","author":"E Cholongitas","year":"2006","unstructured":"Cholongitas E et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol. 2006;125:710\u201321.","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"508_CR26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1665-2681(19)31456-5","volume":"11","author":"A Duarte-Rojo","year":"2012","unstructured":"Duarte-Rojo A, Altamirano JT, Feld JJ. Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. Ann Hepatol. 2012;11(4):426\u201339.","journal-title":"Ann Hepatol"},{"issue":"3","key":"508_CR27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.dld.2015.09.015","volume":"48","author":"S Bernuth","year":"2015","unstructured":"Bernuth S. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Dig Liver Dis. 2015;48(3):291\u20137.","journal-title":"Dig Liver Dis"},{"key":"508_CR28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2036.2010.04500.x","volume":"33","author":"SM Martinez","year":"2011","unstructured":"Martinez SM et al. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2011;33:138\u201348.","journal-title":"Aliment Pharmacol Ther"},{"key":"508_CR29","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-2893.2002.00341.x","volume":"9","author":"T Poynard","year":"2002","unstructured":"Poynard T et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat. 2002;9:128\u201333.","journal-title":"J Viral Hepat"},{"issue":"5","key":"508_CR30","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","volume":"122","author":"T Poynard","year":"2002","unstructured":"Poynard T et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122(5):1303\u201313.","journal-title":"Gastroenterology"},{"issue":"3","key":"508_CR31","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.gastro.2008.05.044","volume":"135","author":"S Maylin","year":"2008","unstructured":"Maylin S et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135(3):821\u20139.","journal-title":"Gastroenterology"},{"issue":"6","key":"508_CR32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","volume":"149","author":"V Mallet","year":"2008","unstructured":"Mallet V et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008;149(6):399\u2013403.","journal-title":"Ann Intern Med"},{"issue":"9","key":"508_CR33","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2036.2008.03639.x","volume":"27","author":"GT Everson","year":"2008","unstructured":"Everson GT et al. The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial. Aliment Pharmacol Ther. 2008;27(9):798\u2013809.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"508_CR34","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","volume":"56","author":"R D\u2019Ambrosio","year":"2012","unstructured":"D\u2019Ambrosio R. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56(2):532\u201343. A morphometric analysis of the liver parenchyma after SVR paired with improvement of liver function.","journal-title":"Hepatology"},{"issue":"2","key":"508_CR35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","volume":"55","author":"European Association for the Study of the Liver","year":"2011","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245\u201364.","journal-title":"J Hepatol"},{"issue":"3","key":"508_CR36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.dld.2015.09.015","volume":"48","author":"S Bernuth","year":"2016","unstructured":"Bernuth S. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Dig Liver Dis. 2016;48(3):291\u20137. Evaluation of fibrosis regression with transient elastography after SVR.","journal-title":"Dig Liver Dis"},{"issue":"1","key":"508_CR37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MEG.0b013e328341b891","volume":"23","author":"ES Andersen","year":"2011","unstructured":"Andersen ES et al. Lower liver stiffness in patients with sustained virological response 4\u00a0years after treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol. 2011;23(1):41\u20134.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"508_CR38","first-page":"e7176","volume":"13","author":"V Calvaruso","year":"2013","unstructured":"Calvaruso V et al. Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance. Hepat Mon. 2013;13(5):e7176.","journal-title":"Hepat Mon"},{"issue":"6","key":"508_CR39","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2036.2011.04765.x","volume":"34","author":"C Hezode","year":"2011","unstructured":"Hezode C et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther. 2011;34(6):656\u201363.","journal-title":"Aliment Pharmacol Ther"},{"key":"508_CR40","first-page":"264A","volume":"62","author":"AM Crissien","year":"2015","unstructured":"Crissien AM et al. Regression of advanced fibrosis or cirrhosis measured by elastography in patients with chronic hepatitis C who achieve sustained virological response after treatment for HCV. Hepatology. 2015;62:264A\u20135A.","journal-title":"Hepatology"},{"issue":"2","key":"508_CR41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2013.03.013","volume":"59","author":"R D\u2019Ambrosio","year":"2013","unstructured":"D\u2019Ambrosio R. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol. 2013;59(2):251\u20136. The authors analyzed transient elastography after HCV cure and called for new cutoff thresholds to stage fibrosis after SVR.","journal-title":"J Hepatol"},{"issue":"41","key":"508_CR42","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.3748\/wjg.v17.i41.4581","volume":"17","author":"K Patel","year":"2011","unstructured":"Patel K et al. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus. World J Gastroenterol. 2011;17(41):4581\u20139.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"508_CR43","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2013.05.015","volume":"59","author":"T Poynard","year":"2013","unstructured":"Poynard T. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59(4):675\u201383. A study reporting fibrosis improvement after SVR utilizing FibroTest.","journal-title":"J Hepatol"},{"issue":"4","key":"508_CR44","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer","year":"2012","unstructured":"European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908\u201343.","journal-title":"J Hepatol"},{"issue":"8","key":"508_CR45","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cgh.2007.02.039","volume":"5","author":"GN Ioannou","year":"2007","unstructured":"Ioannou GN. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007;5(8):938\u201345, 945 e1-4.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"508_CR46","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131(3):174\u201381.","journal-title":"Ann Intern Med"},{"issue":"2","key":"508_CR47","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/cid\/cit234","volume":"57","author":"S Aleman","year":"2013","unstructured":"Aleman S et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57(2):230\u20136.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"508_CR48","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s10620-014-3050-5","volume":"59","author":"E Dieperink","year":"2014","unstructured":"Dieperink E. All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci. 2014;59(4):872\u201380. A Veteran Administration study reporting improvement in overall and liver-related mortality after SVR.","journal-title":"Dig Dis Sci"},{"issue":"12","key":"508_CR49","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40261-015-0338-y","volume":"35","author":"A Messori","year":"2015","unstructured":"Messori A, Badiani B, Trippoli S. Achieving sustained virological response in hepatitis C reduces the long-term risk of hepatocellular carcinoma: an updated meta-analysis employing relative and absolute outcome measures. Clin Drug Investig. 2015;35(12):843\u201350. A meta-analysis of 25 studies around the world documenting a decrease in risk for HCC after SVR.","journal-title":"Clin Drug Investig"},{"issue":"3","key":"508_CR50","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/hep.21492","volume":"45","author":"S Bruno","year":"2007","unstructured":"Bruno S et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45(3):579\u201387.","journal-title":"Hepatology"},{"issue":"4","key":"508_CR51","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.26442","volume":"58","author":"Y Asahina","year":"2013","unstructured":"Asahina Y et al. Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58(4):1253\u201362.","journal-title":"Hepatology"},{"issue":"3","key":"508_CR52","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2010.11.050","volume":"140","author":"AS Lok","year":"2011","unstructured":"Lok AS. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011;140(3):840\u20139, quiz e12.","journal-title":"Gastroenterology"},{"issue":"7","key":"508_CR53","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1053\/j.gastro.2011.03.010","volume":"140","author":"J Bruix","year":"2011","unstructured":"Bruix J et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011;140(7):1990\u20139.","journal-title":"Gastroenterology"},{"issue":"3","key":"508_CR54","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/hep.25869","volume":"56","author":"M Sherman","year":"2012","unstructured":"Sherman M et al. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012;56(3):793\u20136.","journal-title":"Hepatology"},{"issue":"8","key":"508_CR55","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.cgh.2007.02.022","volume":"5","author":"S Roberts","year":"2007","unstructured":"Roberts S et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol. 2007;5(8):932\u20137.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"508_CR56","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP1807","volume":"16","author":"R D\u2019Ambrosio","year":"2011","unstructured":"D\u2019Ambrosio R et al. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon\/ribavirin therapy. Antivir Ther. 2011;16(5):677\u201384.","journal-title":"Antivir Ther"},{"issue":"6","key":"508_CR57","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/hep.23528","volume":"51","author":"S Bruno","year":"2010","unstructured":"Bruno S et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 2010;51(6):2069\u201376.","journal-title":"Hepatology"},{"issue":"3","key":"508_CR58","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R Franchis de","year":"2015","unstructured":"de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743\u201352.","journal-title":"J Hepatol"},{"issue":"2","key":"508_CR59","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10620-012-2380-4","volume":"58","author":"KM Kee","year":"2013","unstructured":"Kee KM et al. Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response. Dig Dis Sci. 2013;58(2):556\u201361.","journal-title":"Dig Dis Sci"},{"issue":"1 Pt 2","key":"508_CR60","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1440-1746.2006.04201.x","volume":"21","author":"H Taniguchi","year":"2006","unstructured":"Taniguchi H et al. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and\/or regression in patients with chronic hepatitis C after interferon therapy. J Gastroenterol Hepatol. 2006;21(1 Pt 2):281\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"508_CR61","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13252","author":"AJ Meer van der","year":"2015","unstructured":"van der Meer AJ. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol. 2015. doi: 10.1111\/jgh.13252 . The authors report improvement of platelet count as a surrogate of decreasing portal hypertension after SVR.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"508_CR62","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","volume":"63","author":"F Poordad","year":"2016","unstructured":"Poordad F. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016;63(5):1493\u2013505. A study with new antiviral agents for advanced cirrhosis and post-transplant HCV recurrence.","journal-title":"Hepatology"},{"key":"508_CR63","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0168-8278(14)60070-2","volume":"60","author":"N Afdhal","year":"2014","unstructured":"Afdhal N et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J Hepatol. 2014;60:S28.","journal-title":"J Hepatol"},{"issue":"7","key":"508_CR64","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/apt.13343","volume":"42","author":"K Deterding","year":"2015","unstructured":"Deterding K et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther. 2015;42(7):889\u2013901.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"508_CR65","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S0168-8278(94)80098-7","volume":"21","author":"R Sallie","year":"1994","unstructured":"Sallie R et al. Recurrence of hepatitis C following orthotopic liver transplantation: a polymerase chain reaction and histological study. J Hepatol. 1994;21(4):536\u201342.","journal-title":"J Hepatol"},{"issue":"11","key":"508_CR66","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/j.1600-6143.2008.02362.x","volume":"8","author":"BJ Veldt","year":"2008","unstructured":"Veldt BJ et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008;8(11):2426\u201333.","journal-title":"Am J Transplant"},{"issue":"10","key":"508_CR67","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/TP.0b013e3181bd783c","volume":"88","author":"N Selzner","year":"2009","unstructured":"Selzner N et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009;88(10):1214\u201321.","journal-title":"Transplantation"},{"issue":"25","key":"508_CR68","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","volume":"371","author":"PY Kwo","year":"2014","unstructured":"Kwo PY et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375\u201382.","journal-title":"N Engl J Med"},{"issue":"6","key":"508_CR69","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.27770","volume":"61","author":"S Pungpapong","year":"2015","unstructured":"Pungpapong S et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015;61(6):1880\u20136.","journal-title":"Hepatology"},{"key":"508_CR70","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2015.0289","author":"S Nair","year":"2016","unstructured":"Nair S, Satapathy SK, Gonzalez HC. Sofosbuvir and simeprevir for treatment of recurrent hepatitis C infection after liver transplant. Exp Clin Transplant. 2016. doi: 10.6002\/ect.2015.0289 .","journal-title":"Exp Clin Transplant"},{"issue":"5","key":"508_CR71","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jhep.2014.12.005","volume":"62","author":"G Askgaard","year":"2015","unstructured":"Askgaard G et al. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study. J Hepatol. 2015;62(5):1061\u20137.","journal-title":"J Hepatol"},{"issue":"3","key":"508_CR72","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/hep.28132","volume":"63","author":"A Berzigotti","year":"2016","unstructured":"Berzigotti A, Saran U, Dufour JF. Physical activity and liver diseases. Hepatology. 2016;63(3):1026\u201340.","journal-title":"Hepatology"},{"issue":"4","key":"508_CR73","first-page":"246","volume":"60","author":"RU Macias-Rodriguez","year":"2014","unstructured":"Macias-Rodriguez RU et al. Changes in hepatic venous pressure gradient induced by a physical exercise program in cirrhotic patients: a randomized open clinical trial. Hepatology. 2014;60(4):246\u2013247A.","journal-title":"Hepatology"},{"issue":"1","key":"508_CR74","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hep.20733","volume":"42","author":"C Hezode","year":"2005","unstructured":"Hezode C et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005;42(1):63\u201371.","journal-title":"Hepatology"},{"issue":"2","key":"508_CR75","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1600-6143.2008.02468.x","volume":"9","author":"DN Ranney","year":"2009","unstructured":"Ranney DN et al. Marijuana use in potential liver transplant candidates. Am J Transplant. 2009;9(2):280\u20135.","journal-title":"Am J Transplant"},{"key":"508_CR76","doi-asserted-by":"crossref","first-page":"95","DOI":"10.12688\/f1000research.6368.2","volume":"4","author":"JJ Feld","year":"2015","unstructured":"Feld JJ. I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. F1000Res. 2015;4:95.","journal-title":"F1000Res"},{"issue":"3","key":"508_CR77","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22694","volume":"49","author":"SL George","year":"2009","unstructured":"George SL et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-years follow-up of 150 patients. Hepatology. 2009;49(3):729\u201338.","journal-title":"Hepatology"},{"issue":"2","key":"508_CR78","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.23691","volume":"52","author":"Y Asahina","year":"2010","unstructured":"Asahina Y et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010;52(2):518\u201327.","journal-title":"Hepatology"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-016-0508-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-016-0508-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-016-0508-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T12:44:29Z","timestamp":1655901869000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-016-0508-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,13]]},"references-count":78,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["508"],"URL":"https:\/\/doi.org\/10.1007\/s11894-016-0508-y","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,13]]},"article-number":"32"}}